Pfizer (PFE) Liabilities from Discontinued Operations (2010 - 2019)

Pfizer (PFE) posted quarterly Liabilities from Discontinued Operations of 2413000000.0 for Q4 2019, up 27.67% YoY from 1890000000.0 in Q4 2018, and up 20.11% sequentially from 2009000000.0 in Q2 2019.

Pfizer (PFE) Liabilities from Discontinued Operations (2010 - 2019) Analysis & Trends

Pfizer has disclosed Liabilities from Discontinued Operations across 6 years of filings, most recently posting 2413000000.0 for Q4 2019.

  • In Q4 2019, Liabilities from Discontinued Operations rose 27.67% year-over-year to 2413000000.0; the TTM figure through Dec 2019 stood at 2413000000.0 (up 27.67% YoY), while the FY2019 annual figure was 2413000000.0, up 27.67% from the prior year.
  • Liabilities from Discontinued Operations advanced to 2413000000.0 in Q4 2019, from 2009000000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for PFE reached as high as 2413000000.0 in Q4 2019 and fell as low as 1890000000.0 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Dec 31, 2019 2.41 Bn
Dec 31, 2019 2.41 Bn
Jun 30, 2019 2.01 Bn
Jun 30, 2019 2.01 Bn
Mar 31, 2019 1.94 Bn
Mar 31, 2019 1.94 Bn
Dec 31, 2018 1.89 Bn
Dec 31, 2018 1.89 Bn
Dec 31, 2013 21.00 Mn
Dec 31, 2013 21.00 Mn
Sep 29, 2013 21.00 Mn
Sep 29, 2013 21.00 Mn
Jun 30, 2013 21.00 Mn
Jun 30, 2013 21.00 Mn
Dec 31, 2012 1.44 Bn
Dec 31, 2012 1.44 Bn
Sep 30, 2012 1.41 Bn
Sep 30, 2012 1.41 Bn
Jul 1, 2012 1.30 Bn
Jul 1, 2012 1.30 Bn